GlassScriptPhysician profile
Patricia De Jesus
NPI 1639379266
$310,260.25
in general payments reported to CMS, 2019-2025
26 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2020: $43K · 2021: $39K · 2022: $43K · 2023: $26K · 2024: $35K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Food and Beverage: $12K · Consulting Fee: $10K · Travel and Lodging: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,631.00 |
| Food and Beverage | $11,925.22 |
| Consulting Fee | $10,200.00 |
| Travel and Lodging | $1,105.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $120,936.77 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Emd Serono, INC. | $64,430.81 | 2019-2025 | Mavenclad, Evobrutinib, Mavenclad |
| Genentech USA, INC. | $35,665.53 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Tg Therapeutics, INC. | $27,390.21 | 2023-2025 | |
| Celgene Corporation | $23,404.58 | 2019-2021 | |
| Genzyme Corporation | $18,117.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $12,778.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,934.84 | 2020-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $1,265.26 | 2019-2025 | Ultomiris, Soliris |
| Horizon Therapeutics Plc | $574.96 | 2021-2023 | Uplizna |
| Janssen Pharmaceuticals, INC | $568.50 | 2019-2025 | Ponvory |
| Amgen INC. | $529.67 | 2021-2025 | Uplizna, Bkemv |
| Abbvie INC. | $502.63 | 2023-2025 | Qulipta |
| Genentech, INC. | $455.51 | 2020-2025 | Ocrevus |
| Banner Life Sciences, LLC | $443.88 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $243.37 | 2023-2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $201.96 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $172.43 | 2019 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $170.88 | 2020-2025 | Emgality, Kisunla, Zepbound |
| Ucb, INC. | $166.89 | 2023-2024 | Rystiggo, Zilbrysq |
| Allergan, INC. | $100.00 | 2019 | |
| Chiesi USA, INC. | $74.86 | 2021-2023 | Cleviprex |
| Sanofi-Aventis U.S. LLC | $63.42 | 2019-2020 | |
| Viiv Healthcare Company | $28.59 | 2021 | |
| Vanda Pharmaceuticals INC. | $20.85 | 2024 | Ponvory |
| Mallinckrodt Hospital Products INC. | $18.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia De Jesus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.